JP7406501B2 - 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体 - Google Patents

薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体 Download PDF

Info

Publication number
JP7406501B2
JP7406501B2 JP2020555188A JP2020555188A JP7406501B2 JP 7406501 B2 JP7406501 B2 JP 7406501B2 JP 2020555188 A JP2020555188 A JP 2020555188A JP 2020555188 A JP2020555188 A JP 2020555188A JP 7406501 B2 JP7406501 B2 JP 7406501B2
Authority
JP
Japan
Prior art keywords
cancer
disease
compound
hydrogen
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521129A5 (https=
JP2021521129A (ja
Inventor
キヤン ナム，
ジェスン キム，
イジン ジョン，
ドンフン ユ，
ムヨン ソ，
ドンシク パク，
ヤン アイクホフ，
グンター ツィシンスキー，
ウーヴェ コッホ，
Original Assignee
キュリエント カンパニー， リミテッド
リード ディスカバリー センター ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリエント カンパニー， リミテッド, リード ディスカバリー センター ゲーエムベーハー filed Critical キュリエント カンパニー， リミテッド
Publication of JP2021521129A publication Critical patent/JP2021521129A/ja
Publication of JP2021521129A5 publication Critical patent/JP2021521129A5/ja
Priority to JP2023131905A priority Critical patent/JP2023138859A/ja
Application granted granted Critical
Publication of JP7406501B2 publication Critical patent/JP7406501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020555188A 2018-04-11 2019-04-11 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体 Active JP7406501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023131905A JP2023138859A (ja) 2018-04-11 2023-08-14 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656041P 2018-04-11 2018-04-11
US62/656,041 2018-04-11
PCT/EP2019/059289 WO2019197546A1 (en) 2018-04-11 2019-04-11 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023131905A Division JP2023138859A (ja) 2018-04-11 2023-08-14 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2021521129A JP2021521129A (ja) 2021-08-26
JP2021521129A5 JP2021521129A5 (https=) 2021-11-11
JP7406501B2 true JP7406501B2 (ja) 2023-12-27

Family

ID=66334384

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555188A Active JP7406501B2 (ja) 2018-04-11 2019-04-11 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
JP2023131905A Withdrawn JP2023138859A (ja) 2018-04-11 2023-08-14 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023131905A Withdrawn JP2023138859A (ja) 2018-04-11 2023-08-14 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Country Status (14)

Country Link
US (1) US11858937B2 (https=)
EP (1) EP3774809A1 (https=)
JP (2) JP7406501B2 (https=)
KR (1) KR20200143429A (https=)
CN (1) CN112334471A (https=)
AU (1) AU2019250504B2 (https=)
BR (1) BR112020020645A2 (https=)
CA (1) CA3095426A1 (https=)
IL (2) IL299105B2 (https=)
MX (1) MX2020010563A (https=)
MY (1) MY207194A (https=)
PH (1) PH12020551638A1 (https=)
SG (1) SG11202009466UA (https=)
WO (1) WO2019197546A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20250263413A1 (en) * 2020-12-02 2025-08-21 Qurient Co., Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
US20240343732A1 (en) * 2021-05-28 2024-10-17 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7(cdk7)
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
EP4493193A1 (en) * 2022-03-18 2025-01-22 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
US20260041693A1 (en) 2022-08-05 2026-02-12 Qurient Co., Ltd. Combination therapy of cdk7 inhibitors with other anti-cancer therapies
KR20240095030A (ko) 2022-12-15 2024-06-25 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130570A1 (en) 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2008130569A1 (en) 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2013128029A1 (en) 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
JP2015511952A (ja) 2012-03-01 2015-04-23 リード ディスカバリー センター ゲーエムベーハー 選択的サイクリン依存性キナーゼ阻害剤としてのピラゾロ−トリアジン誘導体
WO2015154022A1 (en) 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2018507877A (ja) 2015-03-09 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
WO2019035866A1 (en) 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130570A1 (en) 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2008130569A1 (en) 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2013128029A1 (en) 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
JP2015511952A (ja) 2012-03-01 2015-04-23 リード ディスカバリー センター ゲーエムベーハー 選択的サイクリン依存性キナーゼ阻害剤としてのピラゾロ−トリアジン誘導体
WO2015154022A1 (en) 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2018507877A (ja) 2015-03-09 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
WO2019035866A1 (en) 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Also Published As

Publication number Publication date
IL299105B2 (en) 2024-02-01
MY207194A (en) 2025-02-05
US11858937B2 (en) 2024-01-02
AU2019250504B2 (en) 2023-05-18
NZ768400A (en) 2024-07-05
CN112334471A (zh) 2021-02-05
SG11202009466UA (en) 2020-10-29
BR112020020645A2 (pt) 2021-01-12
US20210139483A1 (en) 2021-05-13
EP3774809A1 (en) 2021-02-17
MX2020010563A (es) 2020-10-22
WO2019197546A1 (en) 2019-10-17
IL299105A (en) 2023-02-01
AU2019250504A1 (en) 2020-10-15
JP2023138859A (ja) 2023-10-02
CA3095426A1 (en) 2019-10-17
PH12020551638A1 (en) 2021-07-26
KR20200143429A (ko) 2020-12-23
IL299105B1 (en) 2023-10-01
IL277694A (en) 2020-11-30
JP2021521129A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
JP7406501B2 (ja) 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
JP2023138858A (ja) サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
US11008340B2 (en) Modulators of ROR-gamma
ES2349476T3 (es) Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
CN102482219A (zh) 吡喃酮和吡啶酮衍生物的制备方法
CN100475812C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶
MX2010013842A (es) Naftiridinonas como inhibidores de aurora cinasa.
ES2308260T3 (es) Derivados de imidazopiridinas como inhibidores de no-sintasa inducible.
US12606561B2 (en) Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
WO2002002550A1 (en) Novel pyrazinone derivatives
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
RU2818563C2 (ru) Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
EP4255909A1 (en) Compounds having cyclin-dependent kinase(cdk)-inhibitory function
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
HK40055299A (en) Modulators of ror-gamma
HK1261518A1 (en) Modulators of ror-gamma
HK1261518B (en) Modulators of ror-gamma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231215

R150 Certificate of patent or registration of utility model

Ref document number: 7406501

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150